Caradrin | 466-06-8

• 物质功能分类: 生物化工 - 提取物
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Caradrin
• 英文别名: 5-[(3S,8R,9S,10R,13R,14S,17R)-14-hydroxy-10,13-dimethyl-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy-1,2,3,6,7,8,9,11,12,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one
• CAS: 466-06-8
• 化学式: C₃₀H₄₂O₈
• 分子量: 530.6
• InChiKey: MYEJFUXQJGHEQK-OWBILYANSA-N

物化性质

• 熔点：
  233°C
• 比旋光度：
  D20 -91.5° (CH3OH)
• 沸点：
  530.03°C (rough estimate)
• 密度：
  1.33±0.1 g/cm3 (20 ºC 760 Torr)
• 溶解度：
  二甲基亚砜：100 mg/ml（188.45 mM）
• LogP：
  2.480

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  38
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  126
• 氢给体数：
  4
• 氢受体数：
  8

安全信息

• 危险品标志：
  T
• 危险类别码：
  R25
• 危险品运输编号：
  UN 2811 6.1/PG 3
• WGK Germany：
  3
• RTECS号：
  UK6650000

制备方法与用途

生物活性

Proscillaridin A 是一种强效的拓扑异构酶 I 和 II 抑制剂。它对拓扑异构酶 I 和 II 的 IC50 值分别为 30 nM 和 100 nM。

靶点
Topoisomerase I	30 nM (IC50)
Topoisomerase II	100 nM (IC50)

体外研究

在 MCF-7 细胞中，Proscillaridin A（0-160 nM；48 小时）以时间和剂量依赖性方式揭示了细胞增殖抑制的反应。

文献信息

• DEVICES AND AGENTS FOR DENERVATION
  申请人：Evans, Michael A.

  公开号：EP3246035A1

  公开（公告）日：2017-11-22

  Various delivery devices are described to deliver an agent locally to the renal nerves. The delivery devices are positioned in the renal artery and penetrate into the wall of the renal artery to deliver the agent to the renal nerves. The delivery devices may be used to deliver the agent according to longitudinal position, radial position, and depth of the renal nerves relative to the renal artery. In addition, various methods are described to denervate, modulate, or otherwise affect the renal nerves and other neural tissue. Also, various agents are described to denerve, modulate, or otherwise affect the renal nerves and other neural tissue.

  本文介绍了各种向肾神经局部输送药剂的输送装置。这些给药装置位于肾动脉内，并穿透肾动脉壁，将药剂输送到肾神经。输送装置可根据肾神经相对于肾动脉的纵向位置、径向位置和深度输送药剂。此外，还介绍了各种用于去神经支配、调节或以其他方式影响肾脏神经和其他神经组织的方法。此外，还介绍了用于去神经支配、调节或以其他方式影响肾脏神经和其他神经组织的各种药剂。
• CHEMICAL AND RNAI SUPPRESSORS OF NEUROTOXICITY IN HUNTINGTON'S DISEASE
  申请人：Massachusetts Institute Of Technology

  公开号：EP2646045A1

  公开（公告）日：2013-10-09
• <SUP2/>? <SUB2/>?+? ?NA/K <NS1:SUP>+</NS1:SUP>?ATPASE INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF METASTASIS
  申请人：Universität Basel

  公开号：EP3897657A2

  公开（公告）日：2021-10-27
• Pancreatic cancer treatment using Na+/K+ ATPase inhibitors
  申请人：Khodadoust Mehran

  公开号：US20070105790A1

  公开（公告）日：2007-05-10

  The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach for treating pancreatic cancers. The invention provides the use of Na + e/K + -ATPase inhibitors, such as cardiac glycosides (e.g. ouabain and proscillaridin, etc.), either alone or in combination with other standard therapeutic agents (chemo- or radio-therapies, etc.) for treating pancreatic cancers. The subject Na + /K + -ATPase inhibitors, such as cardiac glycosides, including bufadieneolides or their corresponding aglycones (e.g., proscillaridin, scillaren, and scillarenin, etc.), especially in oral formulations and/or solid dosage forms containing more than 1 mg of active ingredients.
• Combinatorial chemotherapy treatment using Na+/K+ ATPase inhibitors
  申请人：Khodadoust Mehran

  公开号：US20070105789A1

  公开（公告）日：2007-05-10

  The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach to alleviate or eliminate certain negative effects associated with the use of certain cancer treatment agents (e.g. chemotherapy therapeutics, etc.) or regimens (e.g. radio therapies, etc.), including stimulation of the hypoxic stress response in tumor cells. The reagent and pharmaceutical formulation of the invention relates to Na + /K + -ATPase inhibitors, such as cardiac glycosides, including bufadieneolides or their corresponding aglycones (e.g., proscillaridin, scillaren, and scillarenin, etc.), especially in oral formulations and/or solid dosage forms containing more than 1 mg of active ingredients.